A study testing whether a new weekly shot, tirzepatide, can help people with Prader-Willi syndrome lose weight.

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

• Individuals 18-26 years with a BMI in the obesity range (BMI ≥95th percentile for age and sex or ≥30 kg/m2) with either 1) genetically confirmed diagnosis of PWS, 2) hypothalamic obesity as defined by damage to the medial hypothalamic region resulting in dysregulation of satiety and energy balance as diagnosed by a physician, 3) general obesity unrelated to a genetic syndrome or underlying medical condition
• In a stable care setting at least 6 months prior to enrollment
• Able and willing to participate in study visits including tolerating blood draws, urine samples and tolerate DXA scan.
• Ability to take weekly subcutaneous tirzepatide
• Consistent caregiver if they are not independent

Key exclusion criteria

• Current or recent (within 3 months of start of study drug initiation) use of weight loss medications
• Current use of insulin or sulfonylurea or other medication affecting insulin secretion or GLP1 clearance
• Current or prior use of any GLP1A or DPP4 inhibitor during the 6 months before screening
• Any medications that may affect the study endpoints
• Significant weight change (\>3% weight gain or loss) in the last 2 months prior to enrollment